Domenico Coviello

Dr. Domenico Coviello

Director of Laboratory of Human Genetics IRCCS Istituto Giannina Gaslini Research Institute and Children Hospital Via Gerolamo Gaslini 5, 16147 Genova, Italy
orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2011 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FMFrancesca Magri
Francesca Magri
AGAlessandra Govoni
Alessandra Govoni
MDMaria Grazia D’aNgelo
Maria Grazia D’aNgelo
RBRoberto Del Bo
Roberto Del Bo
SGSerena Ghezzi
Serena Ghezzi
GCGiacomo Pietro Comi
Giacomo Pietro Comi

5 May 2010 in European Journal of Human Genetics
Verified
Journal Article
Closed access
HSHeather Skirton
Heather Skirton
CLCeline Lewis
Celine Lewis
AKAlastair Kent
Alastair Kent
DCDomenico Coviello
Domenico Coviello

8 March 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
Carolina BalbiCarolina Balbi
Carolina Balbi
Martina PiccoliMartina Piccoli
Martina Piccoli
Lucio BarileLucio Barile
Lucio Barile
Andrea PapaitAndrea Papait
Andrea Papait
Andrea ArmirottiAndrea Armirotti
Andrea Armirotti
Sveva BolliniSveva Bollini
Sveva Bollini
Human amniotic fluid stem cells (hAFS) have shown a distinct secretory profile and significant regenerative potential in several preclinical models of disease. Nevertheless, little is known about the detailed characterization of their secretome. Herein we show for the first time that hAFS actively release extracellular vesicles (EV) endowed with significant paracrine potential and regenerative effect. c-KIT+ hAFS were isolated from leftover samples of amniotic fluid from prenatal screening and stimulated to enhance EV release (24 hours 20% O2 versus 1% O2 preconditioning). The capacity of the c-KIT+ hAFS-derived EV (hAFS-EV) to induce proliferation, survival, immunomodulation, and angiogenesis were investigated in vitro and in vivo. The hAFS-EV regenerative potential was also assessed in a model of skeletal muscle atrophy (HSA-Cre, SmnF7/F7 mice), in which mouse AFS transplantation was previously shown to enhance muscle strength and survival. hAFS secreted EV ranged from 50 up to 1,000 nm in size. In vitro analysis defined their role as biological mediators of regenerative, paracrine effects while their modulatory role in decreasing skeletal muscle inflammation in vivo was shown for the first time. Hypoxic preconditioning significantly induced the enrichment of exosomes endowed with regenerative microRNAs within the hAFS-EV. In conclusion, this is the first study showing that c-KIT+ hAFS dynamically release EV endowed with remarkable paracrine potential, thus representing an appealing tool for future regenerative therapy. Stem Cells Translational Medicine 2017;6:1340–1355

26 February 2009 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
DGDaniela Giardino
Daniela Giardino
CCCecilia Corti
Cecilia Corti
LBLucia Ballarati
Lucia Ballarati
DCDaniela Colombo
Daniela Colombo
ESElena Sala
Elena Sala
LDLeda Dalprà
Leda Dalprà
Objective: We surveyed the datasheets of 29 laboratories concerning prenatal diagnosis of de novo apparently balanced chromosome rearrangements to assess the involvement of specific chromosomes, the breakpoints distribution and the impact on the pregnancy outcome.Method: By means of a questionnaire, data on 269.371 analyses performed from 1983 to 2006 on amniotic fluid, chorionic villus and fetal blood samples were collected.Results: A total of 246 balanced anomalies were detected at frequencies of 72% for reciprocal translocations, 18% for Robertsonian translocations, 7% for inversions and 3% for complex chromosome rearrangements. The total frequencies of balanced rearrangements were 0.09%, 0.08% and 0.05% on amniotic fluid, chorionic villus and fetal blood samples.Conclusion: A preferential involvement of chromosomes 22, 7, 21, 3, 9 and 11 and a less involvement of chromosomes X, 19, 12, 6 and 1 was observed. A nonrandom distribution of the breakpoints across chromosomes was noticed. Association in the location of recurrent breakpoints and fragile sites was observed for chromosomes 11, 7, 10 and 22, while it was not recorded for chromosome 3. The rate of pregnancy termination was about 20%, with frequencies decreasing from complex chromosomal rearrangements (33%), reciprocal translocations (24%) to inversions (11%) and Robertsonian translocations (3%). Copyright © 2009 John Wiley & Sons, Ltd.

25 April 2006 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
OEOn Behalf Of Eshg And Eshre
On Behalf Of Eshg And Eshre
SSSirpa Soini
Sirpa Soini
DIDolores Ibarreta
Dolores Ibarreta
VAVioletta Anastasiadou
Violetta Anastasiadou
SASégolène Aymé
Ségolène Aymé
HKHelena Kääriäinen
Helena Kääriäinen
The interface between assisted reproductive technologies (ART) and genetics comprises several sensitive and important issues that affect infertile couples, families with severe genetic diseases, potential children, professionals in ART and genetics, health care, researchers and the society in general. Genetic causes have a considerable involvement in infertility. Genetic conditions may also be transmitted to the offspring and hence create transgenerational infertility or other serious health problems. Several studies also suggest a slightly elevated risk of birth defects in children born following ART. Preimplantation genetic diagnosis (PGD) has become widely practiced throughout the world for various medical indications, but its limits are being debated. The attitudes towards ART and PGD vary substantially within Europe. The purpose of the present paper was to outline a framework for development of guidelines to be issued jointly by European Society of Human Genetics and European Society of Human Reproduction and Embryology for the interface between genetics and ART. Technical, social, ethical and legal issues of ART and genetics will be reviewed.

23 January 1998 in Circulation Research
Verified
Journal Article
Open access
PDF file
RBR. Bottinelli
R. Bottinelli
DCDomenico Coviello
Domenico Coviello
CRC. S. Redwood
C. S. Redwood
MPM. A. Pellegrino
M. A. Pellegrino
BMB. J. Maron
B. J. Maron
CRC. Reggiani
C. Reggiani
—Mutant contractile protein genes that cause familial hypertrophic cardiomyopathy (FHC) are presumed to encode mutant proteins that interfere with contractile function. However, it has generally not been possible to show mutant protein expression and incorporation into the sarcomere in vivo. This study aimed to assess whether a mutant α-fast tropomyosin (TM) responsible for FHC is actually expressed and determines abnormal contractile function. Since α-fast TM is expressed in heart and skeletal muscle, samples from vastus lateralis muscles were studied from two FHC patients carrying an Asp 175 Asn α-fast TM mutation and two healthy control subjects. TM isoforms from whole biopsy samples and single fibers were identified by gel electrophoresis and Western blot analysis. An additional faster-migrating TM band was observed in both FHC patients. The aberrant TM was identified as the Asp 175 Asn α-fast TM by comigration with purified recombinant human Asp 175 Asn α-fast TM. Densitometric quantification of mutant and wild-type α-fast TMs suggested equal expression of the two proteins. Contractile parameters of single skinned muscle fibers from FHC patients and healthy control subjects were compared. Calcium sensitivity was significantly increased in muscle fibers containing Asp 175 Asn α-fast Tm compared with fibers lacking the mutant TM. No discernible difference was found regarding cooperativity, maximum force, and maximum shortening velocity. This is the first demonstration that the mutant TM that causes FHC is indeed expressed and almost certainly incorporated into muscle in vivo and does result in altered contractile function; this confirms a dominant-negative, rather than null allele, action. Since the mutant TM was associated with increased calcium sensitivity, this mutation might be associated with an enhancement and not a depression of cardiac contractile performance. If so, this contrasts with the hypothesis that FHC mutations induce contractile impairment followed by compensatory hypertrophy.